Please use this identifier to cite or link to this item:
Title: Antimicrobial use in European long-term care facilities: results from the third point prevalence survey of healthcare-associated infections and antimicrobial use, 2016 to 2017
Author: Ricchizzi, Enrico
Latour, Katrien
Kärki, Tommi
Buttazzi, Rossella
Jans, Béatrice
Moro, Maria Luisa
Nakitanda, Olivia Aya
Plachouras, Diamantis
Monnet, Dominique L.
Suetens, Carl
Kinross, Pete
Limón, Enrique
HALT Study Group
Keywords: Infeccions
Agents antiinfecciosos
Equipaments sanitaris
Anti-infective agents
Health facilities
Issue Date: 15-Nov-2018
Publisher: European Centre for Disease Prevention and Control (ECDC)
Abstract: Antimicrobials are commonly prescribed and contribute to the development of antimicrobial resistance in long-term care facilities (LTCFs). In 2010, the European Centre for Disease Prevention and Control initiated point prevalence surveys (PPS) of healthcare-associated infections and antimicrobial use in European LTCFs, performed by external contractors as the Healthcare-Associated infections in Long-Term care facilities (HALT) projects. Here, we investigated prevalence and characteristics of antimicrobial use and antimicrobial stewardship indicators in European LTCFs in 2016-17. Twenty-four European Union/European Economic Area (EU/EEA) countries, the former Yugoslav Republic of Macedonia and Serbia participated in the third PPS in European LTCFs. Overall, 4.9% (95% confidence interval: 4.8-5.1) of LTCF residents in the EU/EEA participating countries received at least one antimicrobial. The most commonly reported Anatomical Therapeutic Chemical (ATC) groups were beta-lactam antibacterials/penicillins (J01C), other antibacterials (J01X) (e.g. glycopeptide antibacterials, polymyxins), quinolones (J01M), sulfonamides and trimethoprim (J01E), and other beta-lactams (J01D). Urinary tract infections and respiratory tract infections were the main indications for antimicrobial prescription. This PPS provides updated and detailed information on antimicrobial use in LTCFs across the EU/EEA that can be used to identify targets for future interventions, follow-up of these interventions and promote prudent use of antimicrobials in European LTCFs.
Note: Reproducció del document publicat a:
It is part of: Eurosurveillance, 2018, vol. 23, num. 46
Related resource:
ISSN: 1560-7917
Appears in Collections:Articles publicats en revistes (Infermeria de Salut Pública, Salut mental i Maternoinfantil)

Files in This Item:
File Description SizeFormat 
687530.pdf263.09 kBAdobe PDFView/Open

This item is licensed under a Creative Commons License Creative Commons